Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Net Income towards Common Stockholders rose 120.41% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 58.50%. This contributed to the annual value of -$87.9 million for FY2024, which is 46.18% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Net Income towards Common Stockholders of $2.9 million as of Q3 2025, which was up 149.56% from -$5.9 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Net Income towards Common Stockholders peaked at $57.3 million during Q4 2021, and registered a low of -$74.0 million during Q2 2023.
  • For the 3-year period, Mirum Pharmaceuticals' Net Income towards Common Stockholders averaged around -$24.5 million, with its median value being -$23.8 million (2024).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Net Income towards Common Stockholders surged by 253.52% in 2021, and later slumped by 163.60% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $57.3 million in 2021, then plummeted by 163.60% to -$36.4 million in 2022, then grew by 2.12% to -$35.7 million in 2023, then surged by 33.28% to -$23.8 million in 2024, then surged by 120.41% to $2.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at $2.9 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$14.7 million for Q1 2025.